PDCD1 and melanoma: Eventually, high heterogeneity was found in the ORR of anti-PD-1/PD-L1 plus chemotherapy, DCR of the genitourinary system, HNSCC, melanoma, and PFS of anti-PD-1/PD-L1 plus targeted agents.